{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:06:13Z","timestamp":1790283973066,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T00:00:00Z","timestamp":1452038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T00:00:00Z","timestamp":1452038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the TGF-beta superfamily. Recently, several soluble BMP receptors, such as ActRIIA-Fc, ActRIIB-Fc and ALK1-Fc, are undergoing clinical trials. Both BMPRIA and BMPRIB are type I BMP receptors and while BMPRIA-Fc has been reported to have bone-increasing properties, there have been no investigations concerning the biological functions of BMPRIB-Fc. Therefore, comparing the effects of BMPRIA-Fc and BMPRIB-Fc <jats:italic>in vivo<\/jats:italic> should be helpful in revealing the differences in biological function between BMPRIA and BMPRIB and would also aid in the evaluation of BMPRIB-Fc as a therapeutic agent. Here, we produced Tg chimeras in which BMPRIA-Fc and BMPRIB-Fc proteins circulated at high concentrations (36.8\u2013121.4\u2009\u03bcg\/mL). Both Tg chimeras showed a significant increase of bone volume and strength. Using histological analysis, adenoma of the glandular stomach was observed only in BMPRIA-Fc chimeras suggesting the tumorigenic activity of this protein. Administration of recombinant BMPRIB-Fc protein to normal mice also increased bone volumes. Finally, treatment with BMPRIB-Fc decreased the area of osteolytic regions in a mouse model of breast cancer metastasis. In conclusion, our data suggest that BMPRIB-Fc can be used for the treatment of bone-related disorders with a lower risk than BMPRIA-Fc.<\/jats:p>","DOI":"10.1038\/srep18849","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T10:40:05Z","timestamp":1452076805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders"],"prefix":"10.1038","volume":"6","author":[{"given":"Kengo","family":"Yamawaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kakitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Tomizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,6]]},"reference":[{"key":"BFsrep18849_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev.cellbio.21.022404.142018","volume":"21","author":"XH Feng","year":"2005","unstructured":"Feng, X. H. & Derynck, R. Specificity and versatility in tgf-beta signaling through Smads. Annual review of cell and developmental biology 21, 659\u2013693, doi: 10.1146\/annurev.cellbio.21.022404.142018 (2005).","journal-title":"Annual review of cell and developmental biology"},{"key":"BFsrep18849_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","volume":"67","author":"J Massague","year":"1998","unstructured":"Massague, J. TGF-beta signal transduction. Annual review of biochemistry 67, 753\u2013791, doi: 10.1146\/annurev.biochem.67.1.753 (1998).","journal-title":"Annual review of biochemistry"},{"key":"BFsrep18849_CR3","doi-asserted-by":"publisher","first-page":"e78076","DOI":"10.1371\/journal.pone.0078076","volume":"8","author":"K Yamawaki","year":"2013","unstructured":"Yamawaki, K. et al. Adult-specific systemic over-expression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII. PloS one 8, e78076, doi: 10.1371\/journal.pone.0078076 (2013).","journal-title":"PloS one"},{"key":"BFsrep18849_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1210\/er.2002-0003","volume":"23","author":"H Chang","year":"2002","unstructured":"Chang, H., Brown, C. W. & Matzuk, M. M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocrine reviews 23, 787\u2013823 (2002).","journal-title":"Endocrine reviews"},{"key":"BFsrep18849_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/gene.10167","volume":"35","author":"GQ Zhao","year":"2003","unstructured":"Zhao, G. Q. Consequences of knocking out BMP signaling in the mouse. Genesis (New York, NY: 2000) 35, 43\u201356, doi: 10.1002\/gene.10167 (2003).","journal-title":"Genesis (New York, NY: 2000)"},{"key":"BFsrep18849_CR6","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/jbmr.142","volume":"25","author":"AD Chantry","year":"2010","unstructured":"Chantry, A. D. et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 25, 2633\u20132646, doi: 10.1002\/jbmr.142 (2010).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"BFsrep18849_CR7","doi-asserted-by":"publisher","first-page":"18117","DOI":"10.1073\/pnas.0505996102","volume":"102","author":"SJ Lee","year":"2005","unstructured":"Lee, S. J. et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences of the United States of America 102, 18117\u201318122, doi: 10.1073\/pnas.0505996102 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep18849_CR8","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1210\/en.2010-0134","volume":"151","author":"A Koncarevic","year":"2010","unstructured":"Koncarevic, A. et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology 151, 4289\u20134300, doi: 10.1210\/en.2010-0134 (2010).","journal-title":"Endocrinology"},{"key":"BFsrep18849_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1158\/1535-7163.MCT-09-0650","volume":"9","author":"D Mitchell","year":"2010","unstructured":"Mitchell, D. et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Molecular cancer therapeutics 9, 379\u2013388, doi: 10.1158\/1535-7163.MCT-09-0650 (2010).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep18849_CR10","doi-asserted-by":"publisher","first-page":"12207","DOI":"10.1073\/pnas.1204929109","volume":"109","author":"M Baud\u2019huin","year":"2012","unstructured":"Baud\u2019huin, M. et al. A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. Proceedings of the National Academy of Sciences of the United States of America 109, 12207\u201312212, doi: 10.1073\/pnas.1204929109 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep18849_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jcph.160","volume":"53","author":"ML Sherman","year":"2013","unstructured":"Sherman, M. L. et al. Multiple-dose, safety, pharmacokinetic and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. Journal of clinical pharmacology 53, 1121\u20131130, doi: 10.1002\/jcph.160 (2013).","journal-title":"Journal of clinical pharmacology"},{"key":"BFsrep18849_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1078-0432.CCR-13-1840","volume":"20","author":"JC Bendell","year":"2014","unstructured":"Bendell, J. C. et al. Safety, pharmacokinetics, pharmacodynamics and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 480\u2013489, doi: 10.1158\/1078-0432.CCR-13-1840 (2014).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"BFsrep18849_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ajh.23732","volume":"89","author":"KM Attie","year":"2014","unstructured":"Attie, K. M. et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. American journal of hematology 89, 766\u2013770, doi: 10.1002\/ajh.23732 (2014).","journal-title":"American journal of hematology"},{"key":"BFsrep18849_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.12835","volume":"165","author":"KM Abdulkadyrov","year":"2014","unstructured":"Abdulkadyrov, K. M. et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. British Journal of Haematology 165, 814\u2013823, doi: 10.1111\/bjh.12835 (2014).","journal-title":"British Journal of Haematology"},{"key":"BFsrep18849_CR15","doi-asserted-by":"publisher","first-page":"32122","DOI":"10.1074\/jbc.M504629200","volume":"280","author":"S Mazerbourg","year":"2005","unstructured":"Mazerbourg, S. et al. Identification of receptors and signaling pathways for orphan bone morphogenetic protein\/growth differentiation factor ligands based on genomic analyses. The Journal of biological chemistry 280, 32122\u201332132, doi: 10.1074\/jbc.M504629200 (2005).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep18849_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cellsig.2010.10.003","volume":"23","author":"B Bragdon","year":"2011","unstructured":"Bragdon, B. et al. Bone morphogenetic proteins: a critical review. Cellular signalling 23, 609\u2013620, doi: 10.1016\/j.cellsig.2010.10.003 (2011).","journal-title":"Cellular signalling"},{"key":"BFsrep18849_CR17","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1073\/pnas.0500031102","volume":"102","author":"BS Yoon","year":"2005","unstructured":"Yoon, B. S. et al. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 102, 5062\u20135067, doi: 10.1073\/pnas.0500031102 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep18849_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1210\/me.2009-0461","volume":"24","author":"MA Edson","year":"2010","unstructured":"Edson, M. A. et al. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Molecular endocrinology (Baltimore, Md.) 24, 1251\u20131266, doi: 10.1210\/me.2009-0461 (2010).","journal-title":"Molecular endocrinology (Baltimore, Md.)"},{"key":"BFsrep18849_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/en.2010-1390","volume":"153","author":"MM Pulkki","year":"2012","unstructured":"Pulkki, M. M. et al. A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cells. Endocrinology 153, 1509\u20131518, doi: 10.1210\/en.2010-1390 (2012).","journal-title":"Endocrinology"},{"key":"BFsrep18849_CR20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1523\/JNEUROSCI.4459-09.2010","volume":"30","author":"V Sahni","year":"2010","unstructured":"Sahni, V. et al. BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury. The Journal of neuroscience: the official journal of the Society for Neuroscience 30, 1839\u20131855, doi: 10.1523\/JNEUROSCI.4459-09.2010 (2010).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep18849_CR21","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1359\/jbmr.080809","volume":"23","author":"N Kamiya","year":"2008","unstructured":"Kamiya, N. et al. Disruption of BMP Signaling in Osteoblasts Through Type IA Receptor (BMPRIA) Increases Bone Mass. Journal of Bone and Mineral Research 23, 2007\u20132017, doi: 10.1359\/jbmr.080809 (2008).","journal-title":"Journal of Bone and Mineral Research"},{"key":"BFsrep18849_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nature02041","volume":"425","author":"J Zhang","year":"2003","unstructured":"Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836\u2013841, doi: 10.1038\/nature02041 (2003).","journal-title":"Nature"},{"key":"BFsrep18849_CR23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dev.127.3.621","volume":"127","author":"SE Yi","year":"2000","unstructured":"Yi, S. E., Daluiski, A., Pederson, R., Rosen, V. & Lyons, K. M. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 127, 621\u2013630 (2000).","journal-title":"Development"},{"key":"BFsrep18849_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1083\/jcb.200109012","volume":"157","author":"M Zhao","year":"2002","unstructured":"Zhao, M. et al. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. The Journal of cell biology 157, 1049\u20131060, doi: 10.1083\/jcb.200109012 (2002).","journal-title":"The Journal of cell biology"},{"key":"BFsrep18849_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nm1716","volume":"14","author":"MJ Hilton","year":"2008","unstructured":"Hilton, M. J. et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nature medicine 14, 306\u2013314, doi: 10.1038\/nm1716 (2008).","journal-title":"Nature medicine"},{"key":"BFsrep18849_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jbmr.227","volume":"26","author":"EJ Ann","year":"2011","unstructured":"Ann, E. J. et al. Inhibition of Notch1 signaling by Runx2 during osteoblast differentiation. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 26, 317\u2013330, doi: 10.1002\/jbmr.227 (2011).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"BFsrep18849_CR27","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1093\/nar\/gni083","volume":"33","author":"M Kakitani","year":"2005","unstructured":"Kakitani, M. et al. A novel transgenic chimaeric mouse system for the rapid functional evaluation of genes encoding secreted proteins. Nucleic acids research 33, e85, doi: 10.1093\/nar\/gni083 (2005).","journal-title":"Nucleic acids research"},{"key":"BFsrep18849_CR28","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1126\/science.1112521","volume":"309","author":"KA Kim","year":"2005","unstructured":"Kim, K. A. et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science (New York, NY) 309, 1256\u20131259, doi: 10.1126\/science.1112521 (2005).","journal-title":"Science (New York, NY)"},{"key":"BFsrep18849_CR29","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1172\/jci15333","volume":"109","author":"YA Yang","year":"2002","unstructured":"Yang, Y. A. et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. The Journal of clinical investigation 109, 1607\u20131615, doi: 10.1172\/jci15333 (2002).","journal-title":"The Journal of clinical investigation"},{"key":"BFsrep18849_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jbiomech.2004.04.020","volume":"38","author":"JL Schriefer","year":"2005","unstructured":"Schriefer, J. L. et al. A comparison of mechanical properties derived from multiple skeletal sites in mice. Journal of biomechanics 38, 467\u2013475, doi: 10.1016\/j.jbiomech.2004.04.020 (2005).","journal-title":"Journal of biomechanics"},{"key":"BFsrep18849_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/jmg.2004.018598","volume":"41","author":"JR Howe","year":"2004","unstructured":"Howe, J. R. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B and ACVR1 mutations. Journal of Medical Genetics 41, 484\u2013491, doi: 10.1136\/jmg.2004.018598 (2004).","journal-title":"Journal of Medical Genetics"},{"key":"BFsrep18849_CR32","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/bjc.2013.486","volume":"109","author":"PW Voorneveld","year":"2013","unstructured":"Voorneveld, P. W. et al. Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. British journal of cancer 109, 1805\u20131812, doi: 10.1038\/bjc.2013.486 (2013).","journal-title":"British journal of cancer"},{"key":"BFsrep18849_CR33","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1158\/0008-5472.CAN-06-4659","volume":"67","author":"SA Bleuming","year":"2007","unstructured":"Bleuming, S. A. et al. Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer research 67, 8149\u20138155, doi: 10.1158\/0008-5472.CAN-06-4659 (2007).","journal-title":"Cancer research"},{"key":"BFsrep18849_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/ng1430","volume":"36","author":"XC He","year":"2004","unstructured":"He, X. C. et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nature genetics 36, 1117\u20131121, doi: 10.1038\/ng1430 (2004).","journal-title":"Nature genetics"},{"key":"BFsrep18849_CR35","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1158\/1078-0432.CCR-08-3123","volume":"15","author":"A Strube","year":"2009","unstructured":"Strube, A. et al. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption. Clinical cancer research: an official journal of the American Association for Cancer Research 15, 3751\u20133759, doi: 10.1158\/1078-0432.CCR-08-3123 (2009).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"BFsrep18849_CR36","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/onc.2008.232","volume":"27","author":"Y Katsuno","year":"2008","unstructured":"Katsuno, Y. et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27, 6322\u20136333, doi: 10.1038\/onc.2008.232 (2008).","journal-title":"Oncogene"},{"key":"BFsrep18849_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/1471-2407-13-429","volume":"13","author":"M Ampuja","year":"2013","unstructured":"Ampuja, M. et al. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC cancer 13, 429, doi: 10.1186\/1471-2407-13-429 (2013).","journal-title":"BMC cancer"},{"key":"BFsrep18849_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2310\/7290.2008.00018A","volume":"7","author":"F Liu","year":"2008","unstructured":"Liu, F. et al. Humoral bone morphogenetic protein 2 is sufficient for inducing breast cancer microcalcification. Molecular imaging 7, 175\u2013186 (2008).","journal-title":"Molecular imaging"},{"key":"BFsrep18849_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/path.1785","volume":"206","author":"MW Helms","year":"2005","unstructured":"Helms, M. W. et al. First evidence supporting a potential role for the BMP\/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. The Journal of pathology 206, 366\u2013376, doi: 10.1002\/path.1785 (2005).","journal-title":"The Journal of pathology"},{"key":"BFsrep18849_CR40","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/sj.gt.3302483","volume":"12","author":"M Kakeda","year":"2005","unstructured":"Kakeda, M. et al. Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts. Gene Ther 12, 852\u2013856 (2005).","journal-title":"Gene Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18849","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18849.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18849.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:07:04Z","timestamp":1672873624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,10]]}},"alternative-id":["BFsrep18849"],"URL":"https:\/\/doi.org\/10.1038\/srep18849","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,6]]},"assertion":[{"value":"1 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18849"}}